Physician profile
Orel M Everett
NPI 1164509659
$5,263.12
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,915 · 2020: $2,495 · 2021: $853.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,142.73 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $796.25 | 2019-2021 | |
| Amarin Pharma, INC. | $455.84 | 2019-2021 | |
| Lilly USA, LLC | $400.89 | 2019-2021 | |
| Pfizer INC. | $391.04 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $368.15 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $316.66 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $262.83 | 2019-2020 | |
| Allergan, INC. | $187.45 | 2019-2020 | |
| Abbott Laboratories | $159.78 | 2019 | |
| Glaxosmithkline, LLC. | $154.97 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $142.41 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.04 | 2019 | |
| Esperion Therapeutics, INC. | $74.23 | 2020-2021 | |
| Amgen INC. | $70.66 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $66.73 | 2020-2021 | |
| Abbvie INC. | $30.60 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $23.71 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.43 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.29 | 2019 | |
| Melinta Therapeutics, LLC | $16.87 | 2019 | |
| Radius Health, INC. | $16.79 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.50 | 2020 | |
| Astellas Pharma US INC | $12.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orel Everett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.